These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20332294)

  • 21. Transdermal selegiline: new opportunity for managing depression.
    Tobe EH
    J Am Osteopath Assoc; 2008 Feb; 108(2):85-6. PubMed ID: 18303066
    [No Abstract]   [Full Text] [Related]  

  • 22. A case report of high-dose transdermal selegiline in the treatment of major depressive disorder.
    Ashton AK
    Ann Clin Psychiatry; 2009; 21(1):51-2. PubMed ID: 19239833
    [No Abstract]   [Full Text] [Related]  

  • 23. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy for late-life depression.
    Alexopoulos GS
    J Clin Psychiatry; 2011 Jan; 72(1):e04. PubMed ID: 21272511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of monoamine oxidase inhibitors in depression treatment guidelines.
    Thase ME
    J Clin Psychiatry; 2012; 73 Suppl 1():10-6. PubMed ID: 22951237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up after successful electroconvulsive therapy for depression: a 4- to 8-year naturalistic follow-up study.
    van Beusekom BS; van den Broek WW; Birkenhäger TK
    J ECT; 2007 Mar; 23(1):17-20. PubMed ID: 17435567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal selegiline: a novel MAOI formulation for depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2006 Jul; 44(7):9-12. PubMed ID: 17310829
    [No Abstract]   [Full Text] [Related]  

  • 28. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
    Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoamine oxidase inhibitors: should they be discontinued preoperatively?
    el-Ganzouri AR; Ivankovich AD; Braverman B; McCarthy R
    Anesth Analg; 1985 Jun; 64(6):592-6. PubMed ID: 4003777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified electroconvulsive therapy for recurrent major depressive disorder in a meningioma patient: a case report of clinical experience.
    Nakatake M; Teraishi T; Ide M; Wakizono T; Ogawa T; Kuwahara T; Yoshino A; Nomura S
    Fukuoka Igaku Zasshi; 2010 Sep; 101(9):198-206. PubMed ID: 21222352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
    Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC
    CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.
    Shulman KI; Fischer HD; Herrmann N; Huo CY; Anderson GM; Rochon PA
    J Clin Psychiatry; 2009 Dec; 70(12):1681-6. PubMed ID: 19852903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
    Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
    No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures.
    Pae CU; Bodkin JA; Portland KB; Thase ME; Patkar AA
    J Clin Psychiatry; 2012 May; 73(5):661-8. PubMed ID: 22697192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new way to deliver psychiatric meds.
    Levin-Epstein M
    Behav Healthc; 2006 Aug; 26(8):22-3. PubMed ID: 16961036
    [No Abstract]   [Full Text] [Related]  

  • 40. Rehospitalization rate after continued electroconvulsive therapy--a retrospective chart review of patients with severe depression.
    Nordenskjöld A; von Knorring L; Engström I
    Nord J Psychiatry; 2011 Feb; 65(1):26-31. PubMed ID: 20482461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.